Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations

Osteoporosis International

Volumn 17, Issue 7, 2006, Pages 1033-1042

  Gutierrez, G E ^a   Lalka, D ^c   Garrett, I R ^a   Rossini, G ^a   Mundy, G R ^b  

^a OsteoScreen   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

BMP2; Bone formation; HMG CoA reductase inhibitors; Postmenopausal osteoporosis; Statins; Transdermal delivery

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVINOLIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; INTESTINE WALL; LIVER; LIVER TOXICITY; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; RAT; TOXICITY;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANIMALS; BIOMECHANICS; CHOLESTEROL; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; OSTEOCALCIN; OSTEOGENESIS; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33745039765     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-006-0079-0     Document Type: Article

References (39)

1. Mundy GR, Garrett IR, Harris SE, Chan J, Chen D, Rossini G, Boyce BF, Zhao M, Gutierrez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949
2. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H (2000) HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283:3205-3210
3. Wang PS, Solomon DH, Mogun H, Avorn J (2000) HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283:3211-3216
4. Edwards CJ, Hart DJ, Spector TD (2000) Oral statins and increased bone-mineral density in postmenopausal women. Lancet 355:2218-2219
5. Chan AK, Andrade SE, Boles M et al (2000) Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 355:2185-2188
6. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA (2000) HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 85:1137-1142
7. Wada Y, Nakamura Y, Koshiyama H (2000) Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch Intern Med 160:2865
8. van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C (2001) Use of statins and risk of fractures. JAMA 285:1850-1855
9. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, van der Klift M, Pols HA (2004) Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 26 164(2):146-152
10. Hamelin BA, Turgeon J (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19:26-37
11. Henwood JM, Heel RC (1988) Lovastatin: a preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs 36:429-454
12. Germershausen JI, Hunt VM, Bostedor RG, Bailey PJ, Karkas JD, Alberts AW (1989) Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Commun 158:667-675
13. Heller RA, Gould RG (1973) Solubilization and practical purification of hepatic 3-hydroxy-3-methylglutaryl coenzyme a reductase. Biochem Biophys Res Commun 50:859-865
14. Davidson MH (2000) Does differing metabolism by cytochrome P450 add clinical importance? Curr Atheroscler Rep 1:14-19
15. Duggan DE, Vickers S (1990) Physiological disposition of HMG-CoA-reductase inhibitors. Drug Metab Rev 22:333-362
16. Zhou LX, Finley DK, Hassell AE, Holtzman JL (1995) Pharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteers. J Pharmacol Exp Ther 273:121-127
17. Parfitt AM (1988) Bone histomorphometry: standardization of nomenclature, symbols and units. Summary of proposed system. J Bone Miner Res 4:1-5
18. Maeda T, Matsunuma A, Kawane T, Horiuchi N (2001) Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 280:874-877
19. Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ (1985) Midazolam: pharmacology and uses. Anesthesiology 62:310-324
20. Love JN (1994) Beta-blocker toxicity: a clinical diagnosis. Am J Emerg Med 12:356-357
21. Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S (2001) Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol 21:1636
22. Oxlund H, Dalstra M, Andreassen TT (2001) Statin given perorally to adult rats increases cancellous bone mass and compressive strength. Calcif Tissue Int 69:299-304
23. Oxlund H, Andreassen TT (2004) Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation. Bone 34:609-618
24. Wang RW, Kari PH, Lu AYH, Thomas PE, Guengerich FP, Vyas KP (1991) Biotransformation of lovastatin: IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 290:355-361
25. Halpin RA, Ulm EH, Till AE, Kari PH, Vyas KP, Hunninghake DB, Duggan DE (1993) Biotransformation of lovastatin: V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human. Drug Metab Dispos 21:1003-1011
26. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Benet LZ, Sewing KF, Christians U (1999) Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3- methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 27:173-179
27. Chen HS, Gross JF (1980) Intra-arterial infusion of anticancer drugs: theoretic aspects of drug delivery and review of responses. Cancer Treat Rep 64:31-40
28. Bland LB, Garzotto M, DeLoughery TG, Ryan CW, Schuff KG, Wersinger EM, Lemmon D, Beer TM (2005) Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer 103:717-723
29. Utian WH (1987) Transdermal estradiol overall safety profile. Am J Obstet Gynecol 156:1335-1338
30. Wemme H, Pohlenz J, Schonberger W (1995) Effect of oestrogen/gestagen replacement therapy on liver enzymes in patients with Ullrich-Turner syndrome. Eur J Pediatr 154:807-810
31. Arnaud CD (2001) Two years of parathyroid hormone 1-34 and estrogen produce dramatic bone density increases in postmenopausal osteoporotic women that dissipate only slightly during a third year of treatment with estrogen alone: results from a placebo- controlled randomized trial. Bone 28:S77
32. Inkovaara J et al (1975) Prophylactic fluoride treatment and aged bones. Br Med J 3:73-74
33. Gerster JC et al (1983) Bilateral fractures of femoral neck in patients with moderate renal failure receiving fluoride for spinal osteoporosis. Br Med J 287(6394):723-725
34. Dambacher MA et al (1986) Long-term fluoride therapy of postmenopausal osteoporosis. Bone 7:199-205
35. Wozney JM, Rosen V(1998) Bone morphogenetic proteins. In: Mundy JR, Martin TJ (eds) Physiology and pharmacology of bone. Springer-Verlag, Berlin Heidelberg New York, p 725-748
36. Tam CS, Heersche JN, Murray TM, Parsons JA (1982) Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 10:506-512
37. Vyas KP, Kari PH, Prakash SR, Duggan DE (1990) Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes and involvement of cytochrome P-450 in dehydrogenation of lovastatin. Drug Metab Dispos 18:218-222
38. Ping Fang, Lei Dong, Jin-Yan Luo, Xiao-Long Wan, Ke-Xin Du, Ning-Li Chai (2004) Effects of motilin and ursodeoxycholic acid on gastrointestinal myoelectric activity of different origins in fasted rats. World J Gastroenterol 10:2509-2513
39. Chiang JY, Kimmel R, Stroup D (2001) Regulation of cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRalpha). Gene 10 (262):257-265